Oncology News

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among premenopausal women with ER-positive disease who received ovarian suppression, according to a study published in The Lancet Oncology.

The use of current standard HER2 assays as diagnostic tests may result in misassignment of patients for treatment of breast cancer with trastuzumab deruxtecan, according to a study published in JAMA Oncology.

The FDA granted fast track designation to Bria-IMT, an investigational cell-based therapy for the treatment of women with metastatic breast cancer.

A substantial portion of ductal carcinoma in situ recurrences did not appear genetically related to their primary lesions, according to study findings presented at American Association for Cancer Research Annual Meeting.

Younger women with nonmetastatic breast cancer who underwent breast-conserving surgery experienced similar OS as those who underwent mastectomy, according to study results.

COVID-19 restrictions led to a 1.2-fold increase in presentation of late-stage breast cancer at an urban safety-net hospital, according to a study presented at an American Society of Breast Surgeons Annual Meeting press briefing.

Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx breast recurrence scores that would qualify them for adjuvant chemotherapy, according to study results.

Black women are 41% more likely to die of breast cancer than white women, according to American Cancer Society statistics.

Arif Kamal, MD, MBA, MHS, chief patient officer at American Cancer Society, spoke with Healio about two national roundtables the society will launch to drive progress against breast cancer and cervical cancer.